A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy

BACKGROUND: Relugolix is the newest form of androgen deprivation therapy (ADT) approved for prostate cancer. However, as an oral drug, several real-world concerns exist, particularly medication compliance, safety with other androgen receptor-targeted agents, and financial burden to patients. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasparian, Saro, Wei, Oren, Tsai, Ni-Chun, Palmer, Joycelynne, Pal, Sumanta, Lyou, Yung, Dorff, Tanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Genitourinary Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400130/
https://www.ncbi.nlm.nih.gov/pubmed/36888587
http://dx.doi.org/10.1093/oncolo/oyad036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400130/
https://www.ncbi.nlm.nih.gov/pubmed/36888587
http://dx.doi.org/10.1093/oncolo/oyad036

Ejemplares similares